AstraZeneca, UPMC Health Plan sign risk-sharing deal for heart medicine
AstraZeneca and UPMC Health Plan have entered into what they are calling a "pioneering value-based contract" that covers the Pittsburgh-based health insurer's members who are taking Brilinta.
Brilinta is a medication used to lower a patient’s chances of having another heart attack or dying from one in the 12 months following a heart attack.
Under the value-based contract, the reimbursement AstraZeneca receives for its medication will be linked to cardiovascular outcomes for UPMC He alth Plan…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: AstraZeneca | Biotechnology | Cardiology | Cardiovascular | Contracts | Health Management | Heart | Heart Attack | Insurers